Peptide foldamer-based inhibitors of the SARS-CoV-2 S protein–human ACE2 interaction

References

• Cheng RP, Gellman SH, DeGrado WF. β-peptides: from structure to function. Chem Rev. 2001;101(10):3219–3232.
   PubMed Web of Science ®Google Scholar
• Gellman SH. Foldamers: a manifesto. Acc Chem Res. 1998;31(4):173–180.
   Web of Science ®Google Scholar
• Goodman CM, Choi S, Shandler S, DeGrado WF. Foldamers as versatile frameworks for the design and evolution of function. Nat Chem Biol. 2007;3(5):252–262.
   PubMed Web of Science ®Google Scholar
• Martinek TA, Fülöp F. Peptidic foldamers: ramping up diversity. Chem. Soc. Rev. 2012;41(2):687–702.
   PubMed Web of Science ®Google Scholar
• Seebach D, Overhand M, Kühnle FNM, Martinoni B, Oberer L, Hommel U, Widmer H. β Peptides: synthesis by Arndt-Eistert homologation with concomitant peptide coupling. Structure determination by NMR and CD spectroscopy and by X-ray crystallography. Helical secondary structure of a β-hexapeptide in solution and its stability towards Pe. HCA. 1996;79(4):913–941.
   Web of Science ®Google Scholar
• Appella DH, Christianson LA, Klein DA, Powell DR, Huang X, Barchi JJ, Gellman SH. Residue-based control of helix shape in β-peptide oligomers. Nature. 1997;387(6631):381–384.
   PubMed Web of Science ®Google Scholar
• Appella DH, Christianson LA, Klein DA, Richards MR, Powell DR, Gellman SH. Synthesis and structural characterization of helix-forming β-peptides: trans-2-aminocyclopentanecarboxylic acid oligomers. J Am Chem Soc. 1999;121(33):7574–7581.
   Web of Science ®Google Scholar
• Sharma GVM, Jayaprakash P, Narsimulu K, Ravi Sankar A, Ravinder Reddy K, Radha Krishna P, Kunwar AC. A left-handed 9-helix in γ-peptides: synthesis and conformational studies of oligomers with dipeptide repeats of c-linked carbo-γ4-amino acids and γ-aminobutyric acid. Angew Chem Int Ed. 2006;45(18):2944–2947.
   PubMed Web of Science ®Google Scholar
• Arndt H-D, Ziemer B, Koert U. Folding propensity of cyclohexylether-δ-peptides. Org Lett. 2004;6(19):3269–3272.
   PubMed Web of Science ®Google Scholar
• Pilsl LKA, Reiser O. α/β-peptide foldamers: state of the art. Amino Acids. 2011;41(3):709–718.
   PubMed Web of Science ®Google Scholar
• Fülöp F, Martinek TA, Tóth GK. Application of alicyclic β-amino acids in peptide chemistry. Chem Soc Rev. 2006;35(4):323.
   PubMed Web of Science ®Google Scholar
• De Pol S, Zorn C, Klein CD, Zerbe O, Reiser O. Surprisingly stable helical conformations inα/β-peptides by incorporation ofcis-β-aminocyclopropane carboxylic acids. Angew Chem Int Ed. 2004;43(4):511–514.
   PubMed Web of Science ®Google Scholar
• Torres E, Gorrea E, Burusco KK, Da Silva E, Nolis P, Rúa F, Boussert S, Díez-Pérez I, Dannenberg S, Izquierdo S, et al. Folding and self-assembling with β-oligomers based on (1R,2S)-2-aminocyclobutane-1-carboxylic acid. Org Biomol Chem. 2010;8(3):564–575.
   PubMed Web of Science ®Google Scholar
• Shin S, Lee M, Guzei IA, Kang YK, Choi SH. 12/10-helical β-peptide with dynamic folding propensity: coexistence of right- and left-handed helices in an enantiomeric foldamer. J Am Chem Soc. 2016;138(40):13390–13395.
   PubMed Web of Science ®Google Scholar
• Berlicki Ł, Pilsl L, Wéber E, Mándity IM, Cabrele C, Martinek TA, Fülöp F, Reiser O. Unique α,β- and α,α,β,β-peptide foldamers based on cis-β-aminocyclopentanecarboxylic acid. Angew Chem Int Ed. 2012;51(9):2208–2212.
   PubMed Web of Science ®Google Scholar
• Choi SH, Guzei IA, Spencer LC, Gellman SH. Crystallographic characterization of helical secondary structures in α/β-peptides with 1:1 residue alternation. J Am Chem Soc. 2008;130(20):6544–6550.
   PubMed Web of Science ®Google Scholar
• Choi SH, Guzei IA, Spencer LC, Gellman SH. Crystallographic characterization of helical secondary structures in 2:1 and 1:2 α/β-peptides. J Am Chem Soc. 2009;131(8):2917–2924.
   PubMed Web of Science ®Google Scholar
• Mándity IM, Wéber E, Martinek TA, Olajos G, Tóth GK, Vass E, Fülöp F. Design of peptidic foldamer helices: a stereochemical patterning approach. Angew Chem Int Ed. 2009;48(12):2171–2175.
   PubMed Web of Science ®Google Scholar
• Horne WS, Johnson LM, Ketas TJ, Klasse PJ, Lu M, Moore JP, Gellman SH. Structural and Biological mimicry of protein surface recognition by α/β-peptide foldamers. Proc Natl Acad Sci USA. 2009;106(35):14751–14756.
   PubMed Web of Science ®Google Scholar
• Szefczyk M, Węglarz-Tomczak E, Fortuna P, Krzysztoń A, Rudzińska-Szostak E, Berlicki Ł. Controlling the helix handedness of Ααβ-peptide foldamers through sequence shifting. Angew Chem. 2017;129(8):2119–2123.
   Google Scholar
• Cabrele C, Martinek TA, Reiser O, Berlicki Ł. Peptides containing β-amino acid patterns: challenges and successes in medicinal chemistry. J Med Chem. 2014;57(23):9718–9739.
   PubMed Web of Science ®Google Scholar
• Johnson LM, Gellman SH. α-helix mimicry with α/β-peptides. Methods Enzymol. 2013;523:407–429.
   PubMed Web of Science ®Google Scholar
• Girvin ZC, Gellman SH. Foldamer catalysis. J Am Chem Soc. 2020;142(41):17211–17223.
   PubMed Web of Science ®Google Scholar
• Klein M. Stabilized helical peptides: overview of the technologies and its impact on drug discovery. Expert Opin Drug Discov. 2017;12(11):1117–1125.
   PubMed Web of Science ®Google Scholar
• Gopalakrishnan R, Frolov AI, Knerr L, Drury WJ, Valeur E. Therapeutic potential of foldamers: from chemical biology tools to drug candidates? J Med Chem. 2016;59(21):9599–9621.
   PubMed Web of Science ®Google Scholar
• Oba M. Cell-penetrating peptide foldamers: drug-delivery tools. ChemBioChem. 2019;20(16):2041–2045.
   PubMed Web of Science ®Google Scholar
• Arvidsson PI, Ryder NS, Weiss HM, Gross G, Kretz O, Woessner R, Seebach D. Antibiotic and hemolytic activity of a B2/B3 peptide capable of folding into a 12/10-helical secondary structure. Chem Bio Chem. 2003;4(12):1345–1347.
   Google Scholar
• Schmitt MA, Weisblum B, Gellman SH. Interplay among folding, sequence, and lipophilicity in the antibacterial and hemolytic activities of α/β-peptides. J Am Chem Soc. 2007;129 (2):417–428.
   PubMed Web of Science ®Google Scholar
• Lee M-R, Raman N, Gellman SH, Lynn DM, Palecek SP. Hydrophobicity and helicity regulate the antifungal activity of 14-helical β-peptides. ACS Chem Biol. 2014;9(7):1613–1621.
   PubMed Web of Science ®Google Scholar
• Boersma MD, Haase HS, Peterson-Kaufman KJ, Lee EF, Clarke OB, Colman PM, Smith BJ, Horne WS, Fairlie WD, Gellman SH. Evaluation of diverse α/β-backbone patterns for functional α-helix mimicry: analogues of the Bim BH3 domain. J Am Chem Soc. 2012;134(1):315–323.
   PubMed Web of Science ®Google Scholar
• Wójcik P, Berlicki Ł. Peptide-based inhibitors of protein-protein interactions. Bioorg Med Chem Lett. 2015;26(3):707–713.
   PubMedGoogle Scholar
• Stephens OM, Kim S, Welch BD, Hodsdon ME, Kay MS, Schepartz A. Inhibiting HIV fusion with a beta-peptide foldamer. J Am Che. Soc. 2005;127(38):13126–13127.
   PubMed Web of Science ®Google Scholar
• Fortuna P, Twarda-Clapa A, Skalniak L, Ożga K, Holak TA, Berlicki Ł. Systematic ‘Foldamerization’ of peptide inhibiting P53-MDM2/X interactions by the incorporation of trans- or cis-2-aminocyclopentanecarboxylic acid residues. Eur J Med Chem. 2020;208:112814.
   PubMed Web of Science ®Google Scholar
• Checco JW, Gellman SH. Iterative nonproteinogenic residue incorporation yields α/β-Peptides with a helix-loop-helix tertiary structure and high affinity for VEGF. Chem Bio Chem. 2017;18(3):291–299.
   Google Scholar
• Horne WS. Peptide and peptoid foldamers in medicinal chemistry. Expert Opin Drug Discov. 2011;6(12):1247–1262.
   PubMed Web of Science ®Google Scholar
• Bullock BN, Jochim AL, Arora PS. Assessing helical protein interfaces for inhibitor design. J Am Chem Soc. 2011;133(36):14220–14223.
   PubMed Web of Science ®Google Scholar
• Hoffmann M, Kleine-Weber H, Schroeder S, Krüger N, Herrler T, Erichsen S, Schiergens TS, Herrler G, Wu N-H, Nitsche A, et al. SARS-CoV-2 cell entry depends on ACE2 and TMPRSS2 and is blocked by a clinically proven protease inhibitor. Cell. 2020;181(2):271–280.e8.
   PubMed Web of Science ®Google Scholar
• Yan R, Zhang Y, Li Y, Xia L, Guo Y, Zhou Q. Structural basis for the recognition of SARS-CoV-2 by full-length human ACE2. Science. 2020;367(6485):1444–1448.
   PubMed Web of Science ®Google Scholar
• Xu C, Wang Y, Liu C, Zhang C, Han W, Hong X, Wang Y, Hong Q, Wang S, Zhao Q, et al. Conformational dynamics of SARS-CoV-2 trimeric spike glycoprotein in complex with receptor ACE2 revealed by cryo-EM. Sci Adv. 2021;7(1):eabe5575.
   Google Scholar
• Wu L, Chen Q, Liu K, Wang J, Han P, Zhang Y, Hu Y, Meng Y, Pan X, Qiao C, et al. Broad Host range of SARS-CoV-2 and the molecular basis for SARS-CoV-2 binding to cat ACE2. Cell Discov. 2020;6(1):68.
   Web of Science ®Google Scholar
• Panchal D, Kataria J, Patel K, Crowe K, Pai V, Azizogli A, Kadian N, Sanyal S, Roy A, Dodd‐O J, et al. Peptide‐based inhibitors for SARS‐CoV‐2 and SARS‐CoV. Adv Therap. 2021;4(10):2100104.
   Google Scholar
• Schütz D, Ruiz-Blanco YB, Münch J, Kirchhoff F, Sanchez-Garcia E, Müller JA. Peptide and peptide-based inhibitors of SARS-CoV-2 entry. Adv Drug Deliv Rev. 2020;167:47–65.
   PubMed Web of Science ®Google Scholar
• Bojadzic D, Alcazar O, Chen J, Chuang ST, Condor Capcha JM, Shehadeh LA, Buchwald P. Small-molecule inhibitors of the coronavirus spike: ACE2 protein-protein interaction as blockers of viral attachment and entry for SARS-CoV-2. ACS Infect Dis. 2021;7(6):1519–1534.
   PubMed Web of Science ®Google Scholar
• Zhang D, Hamdoun S, Chen R, Yang L, Ip CK, Qu Y, Li R, Jiang H, Yang Z, Chung SK, et al. Identification of natural compounds as SARS-CoV-2 entry inhibitors by molecular docking-based virtual screening with bio-layer interferometry. Pharmacol Res. 2021;172:105820.
   PubMed Web of Science ®Google Scholar
• Carino A, Moraca F, Fiorillo B, Marchianò S, Sepe V, Biagioli M, Finamore C, Bozza S, Francisci D, Distrutti E, et al. Hijacking SARS-CoV-2/ACE2 receptor interaction by natural and semi-synthetic steroidal agents acting on functional pockets on the receptor binding domain. Front Chem. 2020;8:1–15.
   PubMed Web of Science ®Google Scholar
• Pomplun S, Jbara M, Quartararo AJ, Zhang G, Brown JS, Lee YC, Ye X, Hanna S, Pentelute BL. De novo discovery of high-affinity peptide binders for the SARS-CoV-2 spike protein. ACS Cent Sci. 2021;7(1):156–163.
   PubMed Web of Science ®Google Scholar
• Yu L, Wang R, Wen T, Liu L, Wang T, Liu S, Xu H, Wang C. Peptide binder with high-affinity for the SARS-CoV-2 spike receptor-binding domain. ACS Appl Mater Interfaces. 2022;14(25):28527–28536.
   PubMed Web of Science ®Google Scholar
• Pei P, Qin H, Chen J, Wang F, He C, He S, Hong B, Liu K, Qiao R, Fan H, et al. Computational Design of ultrashort peptide inhibitors of the receptor-binding domain of the SARS-CoV-2 s protein. Brief Bioinform. 2021;22(6):bbab243.
   Web of Science ®Google Scholar
• Rajpoot S, Solanki K, Kumar A, Zhang KYJ, Pullamsetti SS, Savai R, Faisal SM, Pan Q, Baig MS. In-silico design of a novel tridecapeptide targeting spike protein of SARS-CoV-2 variants of concern. Int J Pept Res Ther. 2022;28(1):28.
   PubMed Web of Science ®Google Scholar
• Bibilashvili RS, Sidorova MV, Dudkina US, Palkeeva ME, Molokoedov AS, Kozlovskaya LI, Egorov AM, Ishmukhametov AA, Parfyonova EV. Peptide inhibitors of the interaction of the SARS-CoV-2 receptor-binding domain with the ACE2 cell receptor. Biochem Moscow Suppl Ser B. 2021;15(4):274–280.
   PubMedGoogle Scholar
• Kalita P, Tripathi T, Padhi AK. Computational protein design for COVID-19 research and emerging therapeutics. ACS Cent Sci. 2023;9(4):602–613.
   PubMed Web of Science ®Google Scholar
• Morgan DC, Morris C, Mahindra A, Blair CM, Tejeda G, Herbert I, Turnbull ML, Lieber G, Willett BJ, Logan N, et al. Stapled ACE2 peptidomimetics designed to target the SARS-CoV-2 spike protein do not prevent virus internalization. Pept Sci. 2021;113(4):e24217.
   Web of Science ®Google Scholar
• Padhi AK, Seal A, Khan JM, Ahamed M, Tripathi T. Unraveling the mechanism of arbidol binding and inhibition of SARS-CoV-2: insights from atomistic simulations. Eur J Pharmacol. 2021;894:173836.
   PubMed Web of Science ®Google Scholar
• Miki T, Namii K, Seko K, Kakehi S, Moro G, Mihara H. Pattern enrichment analysis for phage selection of stapled peptide ligands. Chem Sci. 2022;13(43):12634–12642.
   PubMed Web of Science ®Google Scholar
• Norman A, Franck C, Christie M, Hawkins PME, Patel K, Ashhurst AS, Aggarwal A, Low JKK, Siddiquee R, Ashley CL, et al. Discovery of cyclic peptide ligands to the SARS-COV-2 spike protein using mrna display. ACS Cent Sci. 2021;7(6):1001–1008.
   PubMed Web of Science ®Google Scholar
• Hampton JT, Lalonde TJ, Tharp JM, Kurra Y, Alugubelli YR, Roundy CM, Hamer GL, Xu S, Liu WR. Novel regioselective approach to cyclize phage-displayed peptides in combination with epitope-directed selection to identify a potent neutralizing macrocyclic peptide for SARS-CoV-2. ACS Chem Biol. 2022;17(10):2911–2922.
   PubMed Web of Science ®Google Scholar
• Kruse M, Altattan B, Laux EM, Grasse N, Heinig L, Möser C, Smith DM, Hölzel R. Characterization of binding interactions of SARS-CoV-2 spike protein and DNA-peptide nanostructures. Sci Rep. 2022;12(1):12828.
   Web of Science ®Google Scholar
• Pramanik A, Mayer J, Sinha SS, Sharma PC, Patibandla S, Gao Y, Corby LR, Bates JT, Bierdeman MA, Tandon R, et al. Human ACE2 peptide-attached plasmonic-magnetic heterostructure for magnetic separation, surface enhanced raman spectroscopy identification, and inhibition of different variants of SARS-CoV-2 infections. ACS Appl Bio Mater. 2022;5(9):4454–4464.
   Google Scholar
• Pramanik A, Sharma PC, Patibandla S, Gao Y, Ruppa-Kasani V, Goli J, Kumar A, Chatterjee A, Sinha SS, Bates JT, et al. Blocking SARS-CoV-2 delta variant (B.1.617.2) spike protein receptor-binding domain binding with the ACE2 receptor of the host cell and inhibiting virus infections using human host defense peptide-conjugated graphene quantum dots. ACS Omega. 2022;7(9):8150–8157.
   PubMed Web of Science ®Google Scholar
• Labriola JM, Miersch S, Chen G, Chen C, Pavlenco A, Saberianfar R, Caccuri F, Zani A, Sharma N, Feng A, et al. Peptide–antibody fusions engineered by phage display exhibit an ultrapotent and broad neutralization of SARS-CoV-2 variants. ACS Chem Biol. 2022;17(7):1978–1988.
   PubMedGoogle Scholar
• Mesias V, St D, Zhu H, Tang X, Dai X, Guo Y, Liu W, Huang J. Effective ACE2 peptide–nanoparticle conjugation and its binding with the SARS-Cov-2 RBD quantified by dynamic light scattering. Chem Commun. 2021;57(57):6979–6982.
   PubMed Web of Science ®Google Scholar
• Cao L, Goreshnik I, Coventry B, Case JB, Miller L, Kozodoy L, Chen RE, Carter L, Walls AC, Park Y-J, et al. De novo design of picomolar SARS-CoV-2 miniprotein inhibitors. Science. 2020;370(6515):426–431.
   PubMed Web of Science ®Google Scholar
• Goddard TD, K DG. Sparky, 3rd ed.; University of California: San Francisco, CA, USA, 2001.
   Google Scholar
• Schwieters CD, Kuszewski JJ, Marius Clore G. Using Xplor-NIH for NMR molecular structure determination. Prog Nucl Magn Reson Spectrosc. 2006;48(1):47–62.
   Web of Science ®Google Scholar
• Martinek TA, Tóth GK, Vass E, Hollósi M, Fülöp F. Cis-2-aminocyclopentanecarboxylic acid oligomers adopt a sheetlike structure: switch from helix to nonpolar strand. Angew Chem Int Ed. 2002;41(10):1718–1721.
   PubMed Web of Science ®Google Scholar
• Yan R, Zhang Y, Li Y, Xia L, Guo Y, Zhou Q. Structural basis for the recognition of SARS-CoV-2 by full-length human ACE2. Science. 2020;367(6485):1444–1448.
   Google Scholar
• Li F, Li W, Farzan M, Harrison SC. Structure of SARS coronavirus spike receptor-binding domain complexed with receptor. Science. 2005;309(5742):1864–1868.
   PubMed Web of Science ®Google Scholar
• Lan J, Ge J, Yu J, Shan S, Zhou H, Fan S, Zhang Q, Shi X, Wang Q, Zhang L, et al. Structure of the SARS-CoV-2 spike receptor-binding domain bound to the ACE2 receptor. Nature. 2020;581(7807):215–220.
   PubMed Web of Science ®Google Scholar
• Benton DJ, Wrobel AG, Xu P, Roustan C, Martin SR, Rosenthal PB, Skehel JJ, Gamblin SJ. Receptor binding and priming of the spike protein of SARS-CoV-2 for membrane fusion. Nature. 2020;588(7837):327–330.
   PubMed Web of Science ®Google Scholar
• Horne WS, Price JL, Gellman SH. Interplay among side chain sequence, backbone composition, and residue rigidification in polypeptide folding and assembly. Proc Natl Acad Sci USA. 2008;105(27):9151–9156.
   PubMed Web of Science ®Google Scholar
• Degorce F. HTRF: a technology tailored for drug discovery – a review of theoretical aspects and recent applications. TOCHGENJ. 2009;3(1):22–32.
   Google Scholar